WO2005016336A1 - Method and composition for treating burned skin - Google Patents

Method and composition for treating burned skin Download PDF

Info

Publication number
WO2005016336A1
WO2005016336A1 PCT/US2004/025260 US2004025260W WO2005016336A1 WO 2005016336 A1 WO2005016336 A1 WO 2005016336A1 US 2004025260 W US2004025260 W US 2004025260W WO 2005016336 A1 WO2005016336 A1 WO 2005016336A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
indomethacin
mixture
moisturizing lotion
steps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/025260
Other languages
English (en)
French (fr)
Inventor
Dittrich D. O. Wayne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LIL BRAT PHARMACEUTICALS
Original Assignee
LIL BRAT PHARMACEUTICALS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIL BRAT PHARMACEUTICALS filed Critical LIL BRAT PHARMACEUTICALS
Priority to JP2006522711A priority Critical patent/JP4890250B2/ja
Priority to AU2004264332A priority patent/AU2004264332B2/en
Priority to CA002524921A priority patent/CA2524921A1/en
Priority to EP04780150A priority patent/EP1656135A1/en
Publication of WO2005016336A1 publication Critical patent/WO2005016336A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to a method and composition for treating burned skin
  • Such exposure may, in some cases, cause sunburn.
  • sunburn may cause irritation and
  • sunburn treatments that provide a spray mist or a petroleum-based composition to the
  • a treatment for sunburn would satisfy several objectives simultaneously.
  • the main objective for the treatment of sunburn would be to relieve pain, eliminate the source
  • treatment for sunburn preferably provides immediate relief from pain while also helping to
  • the sunburn formulation should be any sunscreening or sticking to one's clothing.
  • the sunburn formulation should be any sunscreening or sticking to one's clothing.
  • sunburn Since a sunburn is an inflammatory disorder, sunburn has been treated in the past with
  • the drug behaves as a systemic medicine that passes into the bloodstream for general distribution
  • this drug by the oral mode of administration, particularly over extending periods of therapy.
  • oral administration does not provide for the direct and concentrated application of
  • indomethacin on an affected area such as an area of sunburned skin.
  • Topical hydrocortisone creams or ointments have
  • Topical anesthetic creams or ointments work to
  • the present invention relates to a method and composition for treating mild to
  • the method of the present invention comprises the steps of providing an
  • indomethacin and moisturizing lotion are provided.
  • the indomethacin and moisturizing lotion are
  • the mixture is applied one to two times daily to the
  • composition of the present invention provides a mixture of indomethacin and
  • the mixture provides substantially 100 milligrams of indomethacin per
  • the moisturizing lotion may contain emollients
  • the moisturizing lotion may also contain purified water, glycerin,
  • dimethicone dimethicone, tocopheryl acetate, stearoxytrimethylsilane (and) stearyl alcohol, panthenol,
  • the moisturizing lotion may be marketed under the trade
  • the present invention provides a method and composition for treating sunburned skin
  • the composition includes a mixture of indomethacin and a moisturizing
  • the composition is applied topically to the sunburned skin to provide highly effective
  • the skin may actually act as a
  • anti-inflammatory drugs such as Motrin® and Tolectin®.
  • Cetaphil® provides the appropriate pH and
  • the Cetaphil® provides emollients and humectants which are clinically
  • ceteareth-20 macadamia nut oil, dimethicone, tocopheryl acetate, stearoxytrimethylsilane (and) stearyl alcohol, panthenol, farnesol, benzyl alcohol, phenoxyethanol, acrylates/C 10-30
  • alkyl acrylate crosspolymer sodium hydroxide, and citric acid.
  • indomethacin A stronger or weaker indomethacin mixture may be created depending on
  • the present invention may provide a method and
  • composition for the treatment of mild to moderate skin burns sustained as a result of radiation
  • composition includes a mixture of
  • indomethacin and a moisturizing lotion.
  • the composition is applied topically to the burned
  • composition and method of the present invention are to be
  • composition is applied to the sunburned areas thereby
  • moisturizing lotion provides moisture and a cooling sensation to the sunburned skin
  • indomethacin reduces the inflammation to the skin caused by the sunburn.
  • indomethacin and Cetaphil® should be applied to the sunburned areas one to
  • composition and method may be applied to skin that is burned by

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
PCT/US2004/025260 2003-08-07 2004-08-05 Method and composition for treating burned skin Ceased WO2005016336A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006522711A JP4890250B2 (ja) 2003-08-07 2004-08-05 火傷した皮膚を治療するための方法及び組成物
AU2004264332A AU2004264332B2 (en) 2003-08-07 2004-08-05 Method and composition for treating burned skin
CA002524921A CA2524921A1 (en) 2003-08-07 2004-08-05 Method and composition for treating burned skin
EP04780150A EP1656135A1 (en) 2003-08-07 2004-08-05 Method and composition for treating burned skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/636,404 US7714015B2 (en) 2003-08-07 2003-08-07 Method and composition for treating sunburned skin
US10/636,404 2003-08-07

Publications (1)

Publication Number Publication Date
WO2005016336A1 true WO2005016336A1 (en) 2005-02-24

Family

ID=34116419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025260 Ceased WO2005016336A1 (en) 2003-08-07 2004-08-05 Method and composition for treating burned skin

Country Status (8)

Country Link
US (2) US7714015B2 (enExample)
EP (1) EP1656135A1 (enExample)
JP (1) JP4890250B2 (enExample)
KR (1) KR20060037428A (enExample)
AU (1) AU2004264332B2 (enExample)
CA (1) CA2524921A1 (enExample)
WO (1) WO2005016336A1 (enExample)
ZA (1) ZA200601054B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063173A3 (de) * 2005-03-24 2006-02-23 Beiersdorf Ag Verwendung von zubereitungen zum schutz hauteigener enzyme

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115656A1 (en) * 2007-02-22 2008-09-25 Healing Skin Llc Novel burn treatment composition
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
KR101985886B1 (ko) * 2013-06-24 2019-06-04 주식회사 엘지생활건강 인돌 화합물 및 판테놀을 포함하는 자외선에 의한 피부손상 예방 및 개선용 조성물
US12280144B2 (en) 2019-12-19 2025-04-22 Zaki Yusuf Gel compositions for mitigation of burn injuries, kits containing the gel compositions, and associated methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540572A (en) * 1983-08-29 1985-09-10 Mepha Ag Gel-like ointment containing indometacin
US4933362A (en) * 1989-06-06 1990-06-12 Jack Loomstein Sunburn treatment composition
US5807569A (en) * 1993-05-27 1998-09-15 Smithkline Beecham P.L.C. Topical composition
US20020143047A1 (en) * 2001-01-05 2002-10-03 Galer Bradley S. Methods for treating indomethacin responsive headaches

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US493362A (en) * 1893-03-14 Check-row corn-planter
US3629412A (en) 1969-09-19 1971-12-21 Merck & Co Inc Topical anti-inflammatory agent
US4088754A (en) * 1976-03-02 1978-05-09 Research Corporation Water-soluble cerium (cerous) salts in burn therapy
GB2023000B (en) 1978-06-17 1982-10-13 Kowa Co Antinflammatory analgesic gelled ointments
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
HU185926B (en) 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4384000A (en) * 1980-08-07 1983-05-17 Lanier Earl W Method for treatment of various dermatological conditions
JPS57165313A (en) * 1981-04-07 1982-10-12 Nichibei Zoki Kk Indomethacin for external use
US4847283A (en) 1983-01-10 1989-07-11 Harendza Harinxma Alfred J Ointment and method for treating skin lesions due to herpes virus
US4732755A (en) * 1983-01-17 1988-03-22 University Of Health Sciences/The Chicago Medical School Skin burn treatment
JPS60105613A (ja) * 1983-11-15 1985-06-11 Mitsubishi Chem Ind Ltd インドメタシン外用剤
DE3808039A1 (de) * 1988-03-10 1989-09-21 Bauer Johann Kombinationspraeparat, insbesondere zur behandlung von entzuendlichen prozessen
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
ES2034891B1 (es) * 1991-08-08 1993-12-16 Cusi Lab Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
WO1994026309A1 (fr) * 1993-05-19 1994-11-24 Hisamitsu Pharmaceutical Co., Inc. Agent de solubilisation et preparation externe le contenant
US5558914A (en) 1994-04-11 1996-09-24 Water-Jel Technologies, Inc. Water-based formulation for the treatment of sunburn
JP2723473B2 (ja) * 1994-09-22 1998-03-09 ブーク メデイテツク エイ／エス 硫酸化糖類の用途
CN1102852C (zh) * 1995-11-13 2003-03-12 皮特迈国际有限公司 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物
US6337320B1 (en) 1996-10-11 2002-01-08 Thione International, Inc. Reparatives for ultraviolet radiation skin damage
US20010055599A1 (en) 1997-05-23 2001-12-27 Paul Joseph Drzewiecki Compositions containing select liquid polyol fatty acid polyesters
AUPP229598A0 (en) * 1998-03-11 1998-04-09 Oldfield Family Holdings Pty Limited Treatment of sunburn
US6274627B1 (en) 1999-10-12 2001-08-14 Medinox, Inc. Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
US6399651B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
EP2364734B1 (en) * 2000-07-21 2017-09-06 ReVance Therapeutics, Inc. Multi-component biological transport systems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540572A (en) * 1983-08-29 1985-09-10 Mepha Ag Gel-like ointment containing indometacin
US4933362A (en) * 1989-06-06 1990-06-12 Jack Loomstein Sunburn treatment composition
US5807569A (en) * 1993-05-27 1998-09-15 Smithkline Beecham P.L.C. Topical composition
US20020143047A1 (en) * 2001-01-05 2002-10-03 Galer Bradley S. Methods for treating indomethacin responsive headaches

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALLEN, L. V.JR. AND STILES, M. L.: "Topical indomethacin", US PHARMACIST, vol. 13, no. 12, December 1988 (1988-12-01), pages 52 - 53, XP009039066 *
CHO, M.K. ET AL.: "The effect of topical indomethacin and topical corticosteroid on UVB induced erythema", ANNALS OF DERMATOLOGY, vol. 7, no. 2, April 1995 (1995-04-01), pages 144 - 149, XP009039060 *
KIMURA, T. AND DOI, K.: "Effects of indomethacin on sunburn and suntan reactions in hairless descendent of Mexican hairless dogs", HISTOL HISTOPATHOL, vol. 13, 1998, pages 29 - 36, XP009039061 *
SCHWARZ, T. ET AL.: "Photoprotective effect of topical indomethacin- an experimental study", DERMATOLOGICA, vol. 171, 1985, pages 450 - 458, XP009039065 *
SEKURA SNYDER, D.: "Cutaneous effect of topical indomethacin, an inhibitor of prostaglandin synthesis, on UV-damaged skin", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 64, no. 5, 1975, pages 322 - 325, XP002303274 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063173A3 (de) * 2005-03-24 2006-02-23 Beiersdorf Ag Verwendung von zubereitungen zum schutz hauteigener enzyme

Also Published As

Publication number Publication date
EP1656135A1 (en) 2006-05-17
CA2524921A1 (en) 2005-02-24
JP4890250B2 (ja) 2012-03-07
US7714015B2 (en) 2010-05-11
KR20060037428A (ko) 2006-05-03
US20050031555A1 (en) 2005-02-10
US20050032877A1 (en) 2005-02-10
AU2004264332A1 (en) 2005-02-24
AU2004264332B2 (en) 2010-09-30
US7705032B2 (en) 2010-04-27
ZA200601054B (en) 2007-05-30
JP2007501792A (ja) 2007-02-01

Similar Documents

Publication Publication Date Title
US4285934A (en) Treatment for herpes virus
US5374661A (en) Composition and method for transdermal delivery of diclofenac
US10183076B2 (en) Topical compositions for treatment of irritation of mucous membranes
JPH07504657A (ja) 局所芳香放出組成物
JP2015038119A (ja) 有益な効果を奏するアルギニンの送達
CN108853312A (zh) 聚桂醇外用凝胶及其制备方法
EP0759746B1 (en) A medicated wipe
KR20110074513A (ko) 피부 감염의 국소 치료법
JPH0585523B2 (enExample)
CA2160874C (en) Nasal aromatic releasing compositions
US7705032B2 (en) Method and composition for treating burned skin
US5760085A (en) Topical aromatic releasing compositions
US6562326B1 (en) Topical composition for burn healing
US5278172A (en) Method and composition for treating tendon or joint inflammation using a vasodilator
JP4256125B2 (ja) 外用組成物
US20250143905A1 (en) Topical treatment for anorectal disorders with and without seat cushion
US5331012A (en) Topical pharmaceutical preparation for fever blisters and other viral infections and method of use
US5576329A (en) Method for treating tendon or joint inflammation with papaverine HCL
US20030072828A1 (en) Natural therapeutic composition for the treatment of wounds and sores
CN113274500A (zh) 神经激肽1受体抑制剂的外用制剂及其制备方法
EP1061802B1 (en) Topical carbamazepine formulations and methods of use
JP2001163783A (ja) 皮膚疾患治療用外用剤
US20060216359A1 (en) Topical preparation for treating ulcerations on the inside of the month
JP2007308403A (ja) 皮膚外用剤
Dirschka et al. Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2524921

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004780150

Country of ref document: EP

Ref document number: 2006/01054

Country of ref document: ZA

Ref document number: 200601054

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006522711

Country of ref document: JP

Ref document number: 1020067002636

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004264332

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004264332

Country of ref document: AU

Date of ref document: 20040805

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004264332

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067002636

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004780150

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)